Investor Relations

INVESTORS & MEDIA

INVESTORS
& MEDIA

We are a leading science and technology company that delivers life-transforming medicines for serious diseases.

Founded by physician-scientists nearly 30 years ago, our science-driven approach has resulted in five FDA-approved medicines and numerous product candidates in a range of diseases, including cancer, rheumatoid arthritis, asthma, pain and infectious diseases.

In addition to our medicines, our innovations include the VelociSuite® technologies, world-class manufacturing operations, one of the largest human sequencing efforts in the world and rapid response technologies being used for global good.

 

NASDAQ REGN

$369.61 0.51 (0.14)%

High 374.94 Low 369.05 Volume 360,665 Market Cap 38.50B
04/24/17 12:48 PM ET | Minimum 20 minutes delay.

Stock information provided by eSignal.

Financial information

NEWSROOM

  • Apr 24

    Regeneron and Sanofi Receive Positive CHMP Opinion for Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis

    Read on
  • Apr 14

    Regeneron to Report First Quarter 2017 Financial and Operating Results and Host Conference Call and Webcast on May 4, 2017

    Read on

EVENTS

  • Regeneron Pharmaceuticals Q1 2017 Earnings Conference Call
    May 4, 2017 | 8:30 AM

  • 2017 Annual Meeting of Shareholders
    Jun 9, 2017 | 10:30 AM ET

Events & Presentations

NASDAQ REGN

$369.61 0.51 (0.14)%

High 374.94 Low 369.05 Volume 360,665 Market Cap 38.50B
04/24/17 12:48 PM ET | Minimum 20 minutes delay.

Stock information provided by eSignal.

Stock information

Financial information